Search for a trial

Seizure Treatment IN Glioma (STING): comparing a treatment strategy with levetiracetam versus treatment with valproic acid in glioma patients with a first seizure

The overall aim of this strategy study is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with de novo seizures. In addition, we aim to examine the level of toxicity, the impact of seizures…

Mean arterial pressure alarm compared to hypotension prediction index in preventing intraoperative hypotension

Primary Objective: The performance in preventing intraoperative hypotension of a MAP treatment alarm of 72 mmHg compared to the performance of the HPI alarm. Secondary Objectives: - The correlation between the MAP signal and HPI signal - The…

Hydra study

To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with `standard' management by CTPA alone in a…

The prospective data collection initiative on on small bowel, colorectal and anal cancer - a prospective observational cohort study.

The main objectives of this project are:- To start a prospective observational cohort study of patients who have been diagnosed with CRC, small bowel and anal cancer and follow them from time of diagnosis until death.- To prospectively collect data…

Optimal postoperative chest tube and pain management in patients surgically treated for primary spontaneous pneumothorax; a randomized controlled trial.

Our objective is to compare the efficacy of early chest tube removal combined with single-shot PVB versus standard treatment (chest tube for at least 3 days and thoracic epidural analgesia (TEA)) after surgery for PSP. Efficacy is defined as…

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…

Clinical Performance Study Protocol for Use of VENTANA PD-L1 (SP263)
CDx Assay in [redacted]

The objective of this study is to establish the clinical performance of VENTANA PD-L1 (SP263) CDx Assay as a companion diagnostic (CDx) for the identification of patients with NSCLC who may benefit from treatment with [redacted]. …